Rockefeller Capital Management L.P. Increases Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Rockefeller Capital Management L.P. lifted its stake in Becton, Dickinson and Company (NYSE:BDX) by 1.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 520,903 shares of the medical instruments supplier’s stock after acquiring an additional 5,051 shares during the quarter. Rockefeller Capital Management L.P. owned 0.18% of Becton, Dickinson and Company worth $125,590,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BDX. Livelsberger Financial Advisory purchased a new position in Becton, Dickinson and Company in the third quarter valued at $26,000. Ashton Thomas Securities LLC purchased a new stake in shares of Becton, Dickinson and Company during the third quarter worth approximately $33,000. Tompkins Financial Corp raised its holdings in Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 46 shares in the last quarter. Sound Income Strategies LLC lifted its stake in Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 44 shares during the last quarter. Finally, Opal Wealth Advisors LLC acquired a new position in Becton, Dickinson and Company during the 2nd quarter worth approximately $45,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Evercore ISI increased their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Finally, Raymond James dropped their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $283.00.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX opened at $221.98 on Friday. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $249.89. The company has a 50-day moving average price of $234.39 and a 200 day moving average price of $234.23. The company has a market cap of $64.16 billion, a P/E ratio of 37.37, a PEG ratio of 1.65 and a beta of 0.43. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. Becton, Dickinson and Company’s quarterly revenue was up 6.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.42 earnings per share. Research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Monday, December 9th will be issued a dividend of $1.04 per share. The ex-dividend date is Monday, December 9th. This represents a $4.16 dividend on an annualized basis and a yield of 1.87%. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s payout ratio is currently 63.97%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.